Skip to main content
SpringerLink
Log in

Investment in effective migraine therapy could reduce the overall costs of the disorder

  • Drugs Economics and Quality of Life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Coukell AJ, Lamb HM. Sumatriptan: a pharmacoeconomic review of its use in migraine. Pharmacoeconomics 1997 May; 11(5): 473–90

    Article  PubMed  CAS  Google Scholar 

  2. Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 1998 Jun; 13(6): 667–76

    Article  PubMed  CAS  Google Scholar 

  3. Parry TG. The prevalence and costs of migraine in Australia. Kensington: University of New South Wales, 1992. Centre for Applied Economic Research (CAER) working paper no.: 1992/1

    Google Scholar 

  4. O’Brien B, Goeree R, Streiner D. Prevalence of migraine headache in Canada: a population-based survey. Int J Epidemiol 1994; 23: 1020–6

    Article  PubMed  Google Scholar 

  5. van Roijen L, Essink-Bot M-L, Koopmanschap MA, et al. Societal perspective on the burden of migraine in The Netherlands. Pharmacoeconomics 1995; 7(2): 170–9

    Article  PubMed  Google Scholar 

  6. Láinez JM, Titus F, Cobaleda S, et al. Socioeconomic impact of migraine [abstract]. Funct Neurol 1996; 11: 133

    Google Scholar 

  7. Björk S, Roos P. Economic aspects of migraine in Sweden. Lund: Institute for Health Economics, 1991. Working paper no.: 8

    Google Scholar 

  8. Blau JN, Drummond MR Migraine. Office of Health Economics (OHE). London: OHE, 1991

    Google Scholar 

  9. Cull RE, Wells NEJ, Miocevich ML. The economic cost of migraine. Br J Med Econ 1992; 2: 103–15

    Google Scholar 

  10. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 1992; 2(1): 67–76

    Article  PubMed  CAS  Google Scholar 

  11. Streator SE, Shearer SW. Pharmacoeconomic impact of injectable sumatriptan on migraine-associated healthcare costs. Am J Manage Care 1996; 2: 139–43

    Google Scholar 

  12. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache 1993; 33: 29–35

    Article  PubMed  CAS  Google Scholar 

  13. Bloomberg Financial Markets. Electronic database. New York: LP Bloomberg, 1998

  14. International Monetary Fund (IMF). International financial statistics. Vol. 11 (1). Washington, DC: IMF, 1998

    Google Scholar 

  15. Tailor drug choice to headache severity in acute migraine attacks. Drug Ther Perspect 1999 May 24; 13(10): 8–11

    Google Scholar 

  16. Alot of ammunition but does migraine prophylaxis hit the target? Drug Ther Perspect 1999 Jun 7; 13(11): 5–8

    Google Scholar 

  17. Solomon GD, Price KL. Burden of migraine: a review of its socioeconomic impact. Pharmacoeconomics 1997; 11 Suppl. 1: 1–10

    Article  PubMed  Google Scholar 

  18. Welch KMA. Drug therapy of migraine. N Engl J Med 1993 Nov 11; 329: 1476–83

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Investment in effective migraine therapy could reduce the overall costs of the disorder. Drugs Ther. Perspect 14, 14–16 (1999). https://doi.org/10.2165/00042310-199914010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199914010-00005

Keywords

Search

Navigation